...
首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >EFFECT OF CHLOROPHYLLIN, AN SEMI-SYNTHETIC CHLOROPHYLL MOLECULE ON HYPERGLYCEMIA AND HYPERLIPIDEMIA IN STREPTOZOTOCIN INDUCED DIABETIC MICE
【24h】

EFFECT OF CHLOROPHYLLIN, AN SEMI-SYNTHETIC CHLOROPHYLL MOLECULE ON HYPERGLYCEMIA AND HYPERLIPIDEMIA IN STREPTOZOTOCIN INDUCED DIABETIC MICE

机译:半合成叶绿素叶绿素对链脲佐菌素诱导的糖尿病小鼠高糖血症和高脂血症的影响

获取原文

摘要

Objective: The aim of the present study was to determine the effect of chlorophyllin (CHL) on hyperglycemia and hyperlipidemia in streptozotocin (STZ) induced diabetic mice. Methods: Diabetes was induced in mice by administering 150 mg/kg body weight (bw) dose of STZ. The effect of 10, 25, 50 and 100 mg/kg bw doses of CHL on hyperglycemia was examined in diabetic mice for the acute and sub-acute period. The intraperitoneal glucose tolerance test (IPGTT) was performed in diabetic (Group A) as well as diabetic treated with CHL (Group B), metformin (Group C), glibenclamide (Group D), and insulin (Group E) groups. The percent glycosylated hemoglobin (GHb%) level, lipid profile, and atherogenic index (AI) were determined in normal (Group A), diabetic (Group B) as well as diabetic treated with CHL (Group C), and metformin (Group D) groups. Results: In both acute and sub-acute antihyperglycemic study, 50 mg/kg bw dose of CHL was found effective in reduction of blood glucose level significantly and considered as an optimum dose. In IPGTT, the significant reduction of blood glucose level in Group B was observed at 2 h (h) and 4 h in comparison with Group A. The GHb%, lipid profile and AI value of Group C were found significantly different from Group B in the study. Conclusion: The present study justifies the antihyperglycemic and antihyperlipidemic effects of CHL in STZ induced diabetic mice, hence suggesting its beneficial effect in the treatment of diabetes.
机译:目的:本研究的目的是确定叶绿素(CHL)对链脲佐菌素(STZ)诱导的糖尿病小鼠高血糖和高血脂的影响。方法:给予150 mg / kg体重(bw)的STZ诱发小鼠糖尿病。在糖尿病小鼠的急性和亚急性时期,检查了10、25、50和100 mg / kg bw剂量的CHL对高血糖症的影响。在糖尿病组(A组)以及接受CHL治疗的糖尿病患者(B组),二甲双胍(C组),格列本脲(D组)和胰岛素(E组)进行了腹膜内葡萄糖耐量测试(IPGTT)。测定正常(A组),糖尿病(B组)以及接受CHL(C组)和二甲双胍(D组)治疗的糖尿病患者的糖基化血红蛋白(GHb%)水平,脂质分布和动脉粥样硬化指数(AI) )组。结果:在急性和亚急性降血糖研究中,发现50 mg / kg bw剂量的CHL可以有效降低血糖水平,被认为是最佳剂量。在IPGTT中,与A组相比,B组在2 h(h)和4 h血糖水平显着降低。发现C组的GHb%,脂质分布和AI值与B组显着不同。研究。结论:本研究证明了CHL在STZ诱导的糖尿病小鼠中的降血糖和降血脂作用是合理的,因此表明其在糖尿病治疗中具有有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号